Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
3485 | 1894 | 44.2 | 91% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CYCLIN D1 | Author keyword | 102 | 20% | 24% | 447 |
2 | CYCLIN E | Author keyword | 38 | 25% | 7% | 131 |
3 | CCND1 | Author keyword | 27 | 37% | 3% | 57 |
4 | CYCLIN D1B | Author keyword | 18 | 89% | 0% | 8 |
5 | G870A | Author keyword | 14 | 100% | 0% | 7 |
6 | CYCLIN D1 GENE | Author keyword | 12 | 86% | 0% | 6 |
7 | CYCLIN D3 | Author keyword | 10 | 24% | 2% | 36 |
8 | CDK4 | Author keyword | 8 | 14% | 3% | 54 |
9 | CYCLIN D2 | Author keyword | 7 | 22% | 2% | 29 |
10 | CYCLIN D | Author keyword | 7 | 17% | 2% | 36 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CYCLIN D1 | 102 | 20% | 24% | 447 | Search CYCLIN+D1 | Search CYCLIN+D1 |
2 | CYCLIN E | 38 | 25% | 7% | 131 | Search CYCLIN+E | Search CYCLIN+E |
3 | CCND1 | 27 | 37% | 3% | 57 | Search CCND1 | Search CCND1 |
4 | CYCLIN D1B | 18 | 89% | 0% | 8 | Search CYCLIN+D1B | Search CYCLIN+D1B |
5 | G870A | 14 | 100% | 0% | 7 | Search G870A | Search G870A |
6 | CYCLIN D1 GENE | 12 | 86% | 0% | 6 | Search CYCLIN+D1+GENE | Search CYCLIN+D1+GENE |
7 | CYCLIN D3 | 10 | 24% | 2% | 36 | Search CYCLIN+D3 | Search CYCLIN+D3 |
8 | CDK4 | 8 | 14% | 3% | 54 | Search CDK4 | Search CDK4 |
9 | CYCLIN D2 | 7 | 22% | 2% | 29 | Search CYCLIN+D2 | Search CYCLIN+D2 |
10 | CYCLIN D | 7 | 17% | 2% | 36 | Search CYCLIN+D | Search CYCLIN+D |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | A870G POLYMORPHISM | 79 | 87% | 2% | 39 |
2 | CCND1 | 46 | 73% | 2% | 35 |
3 | D1 POLYMORPHISM | 45 | 94% | 1% | 16 |
4 | G870A POLYMORPHISM | 41 | 85% | 1% | 22 |
5 | E OVEREXPRESSION | 38 | 64% | 2% | 37 |
6 | DEPENDENT KINASES | 19 | 11% | 9% | 165 |
7 | CANDIDATE ONCOGENE | 18 | 27% | 3% | 58 |
8 | D1 OVEREXPRESSION | 18 | 45% | 2% | 30 |
9 | G1 | 16 | 13% | 6% | 116 |
10 | CHROMOSOME 11Q13 | 15 | 25% | 3% | 55 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Nuclear Cyclin D1: An Oncogenic Driver in Human Cancer | 2009 | 170 | 61 | 69% |
Cyclin D as a therapeutic target in cancer | 2011 | 254 | 182 | 44% |
Minireview: Cyclin D1: Normal and abnormal functions | 2004 | 521 | 118 | 45% |
Cyclin D1: polymorphism, aberrant splicing and cancer risk | 2006 | 197 | 129 | 71% |
New Roles of Cyclin D1 | 2013 | 28 | 59 | 54% |
Living with or without cyclins and cyclin-dependent kinases | 2004 | 544 | 104 | 38% |
Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present | 2014 | 14 | 117 | 38% |
Cyclin D1 in breast cancer pathogenesis | 2005 | 148 | 96 | 75% |
The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention | 2007 | 227 | 149 | 31% |
Cancer cell cycles | 1996 | 3982 | 180 | 16% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | LEONARD MADLYN ABRAMSON FAMILY CANC | 4 | 28% | 0.6% | 12 |
2 | CVM MBS | 3 | 100% | 0.2% | 3 |
3 | MANCHESTER HLTH SCI PATERSON CANC R | 3 | 50% | 0.2% | 4 |
4 | EA 3919 | 2 | 38% | 0.3% | 5 |
5 | PERINATOGYNECOL | 2 | 38% | 0.3% | 5 |
6 | CANC ENABLING SCI TECHNOLCHRISTIE NHS FDN | 2 | 50% | 0.2% | 3 |
7 | UNIT 0066 | 2 | 50% | 0.2% | 3 |
8 | MEDCANC EASTERN FINLAND | 2 | 43% | 0.2% | 3 |
9 | TUMOR CELL BIOL 332 N LAUDERDALE | 1 | 50% | 0.1% | 2 |
10 | OBSTET GYNECOLKANGNAM KU | 1 | 40% | 0.1% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000171097 | CCNG2//CYCLIN G2//CYCLIN G |
2 | 0.0000166232 | SKP2//P27KIP1//P27 |
3 | 0.0000153845 | FBXW7//FBW7//HCDC4 |
4 | 0.0000110830 | P14ARF//P16//P16INK4A |
5 | 0.0000110562 | FLAVOPIRIDOL//CELL CYCLE REGULAT GRP//ROSCOVITINE |
6 | 0.0000109655 | CAK//CDC2//CYCLIN A1 |
7 | 0.0000105812 | E2F//P107//P130 |
8 | 0.0000103248 | P21//P21WAF1 CIP1//WAF1 |
9 | 0.0000079389 | EPITHELIAL CANC BIOL//TUMOR FRONT GRADING//INVASIVE TUMOUR FRONT |
10 | 0.0000076461 | CDK2AP1//DOC 1//P12CDK2 AP1 |